A Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of KMRC011

NCT03585803 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Radiation Syndrome

Interventions

DRUG: KMRC011 5μg or Placebo
DRUG: KMRC011 10μg or Placebo
DRUG: KMRC011 15μg or Placebo
DRUG: KMRC011 20μg or Placebo
DRUG: KMRC011 25μg or Placebo

Sponsor

Intron Biotechnology, Inc.